Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
USPH vs CCRN vs HCSG vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Equipment & Services
USPH vs CCRN vs HCSG vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Equipment & Services |
| Market Cap | $897M | $423M | $1.60B | $6.63B |
| Revenue (TTM) | $695M | $761M | $1.84B | $2.35B |
| Net Income (TTM) | $11M | $-99M | $59M | $128M |
| Gross Margin | 22.0% | 18.2% | 13.3% | 69.7% |
| Operating Margin | 12.2% | -0.9% | 3.0% | 4.6% |
| Forward P/E | 20.6x | 133.8x | 20.8x | 51.5x |
| Total Debt | $426M | $2M | $25M | $1.12B |
| Cash & Equiv. | $36M | $109M | $161M | $229M |
USPH vs CCRN vs HCSG vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
| Cross Country Healt… (CCRN) | 100 | 215.7 | +115.7% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| Hims & Hers Health,… (HIMS) | 100 | 258.4 | +158.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: USPH vs CCRN vs HCSG vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
USPH has the current edge in this matchup, primarily because of its strength in value and dividends.
- Lower P/E (20.6x vs 51.5x)
- 3.1% yield; 5-year raise streak; the other 3 pay no meaningful dividend
CCRN is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
- Beta 0.78 vs HIMS's 2.40, lower leverage
HCSG is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 20 yrs, beta 1.12
- +55.8% vs HIMS's -51.0%
- 7.3% ROA vs CCRN's -19.8%, ROIC 9.0% vs -0.9%
HIMS is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 161.9% 10Y total return vs USPH's 22.6%
- 59.0% revenue growth vs CCRN's -21.6%
- 5.5% margin vs CCRN's -13.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (20.6x vs 51.5x) | |
| Quality / Margins | 5.5% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.78 vs HIMS's 2.40, lower leverage | |
| Dividends | 3.1% yield; 5-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +55.8% vs HIMS's -51.0% | |
| Efficiency (ROA) | 7.3% ROA vs CCRN's -19.8%, ROIC 9.0% vs -0.9% |
USPH vs CCRN vs HCSG vs HIMS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
USPH vs CCRN vs HCSG vs HIMS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HIMS leads in 2 of 6 categories
HCSG leads 2 • USPH leads 0 • CCRN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HIMS is the larger business by revenue, generating $2.3B annually — 3.4x USPH's $695M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $695M | $761M | $1.8B | $2.3B |
| EBITDAEarnings before interest/tax | $107M | $9M | $72M | $164M |
| Net IncomeAfter-tax profit | $11M | -$99M | $59M | $128M |
| Free Cash FlowCash after capex | $67M | $41M | $139M | $73M |
| Gross MarginGross profit ÷ Revenue | +22.0% | +18.2% | +13.3% | +69.7% |
| Operating MarginEBIT ÷ Revenue | +12.2% | -0.9% | +3.0% | +4.6% |
| Net MarginNet income ÷ Revenue | +1.5% | -13.0% | +3.2% | +5.5% |
| FCF MarginFCF ÷ Revenue | +9.6% | +5.4% | +7.6% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.7% | -100.0% | +6.6% | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -115.0% | -6.0% | +175.0% | -27.3% |
Valuation Metrics
Evenly matched — USPH and CCRN each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 27.5x trailing earnings, HCSG trades at a 45% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, USPH's 12.5x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $897M | $423M | $1.6B | $6.6B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $317M | $1.5B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | 41.55x | -4.47x | 27.54x | 50.32x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.63x | 133.84x | 20.83x | 51.51x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 12.52x | 23.75x | 22.38x | 42.68x |
| Price / SalesMarket cap ÷ Revenue | 1.15x | 0.40x | 0.87x | 2.82x |
| Price / BookPrice ÷ Book value/share | 1.16x | 1.31x | 3.19x | 12.25x |
| Price / FCFMarket cap ÷ FCF | 14.71x | 10.55x | 11.49x | 89.61x |
Profitability & Efficiency
HCSG leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +1.4% | -27.1% | +11.8% | +23.7% |
| ROA (TTM)Return on assets | +0.9% | -19.8% | +7.3% | +6.0% |
| ROICReturn on invested capital | +5.6% | -0.9% | +9.0% | +10.7% |
| ROCEReturn on capital employed | +7.6% | -0.8% | +7.7% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.55x | 0.01x | 0.05x | 2.07x |
| Net DebtTotal debt minus cash | $390M | -$106M | -$136M | $892M |
| Cash & Equiv.Liquid assets | $36M | $109M | $161M | $229M |
| Total DebtShort + long-term debt | $426M | $2M | $25M | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | 15.42x | -1.39x | 33.02x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $5,664 for USPH. Over the past 12 months, HCSG leads with a +55.8% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -24.6% | +62.4% | +28.6% | -23.2% |
| 1-Year ReturnPast 12 months | -14.3% | -5.4% | +55.8% | -51.0% |
| 3-Year ReturnCumulative with dividends | -43.7% | -44.3% | +48.6% | +116.6% |
| 5-Year ReturnCumulative with dividends | -43.4% | -22.5% | -21.1% | +137.6% |
| 10-Year ReturnCumulative with dividends | +22.6% | -10.5% | -26.8% | +161.9% |
| CAGR (3Y)Annualised 3-year return | -17.4% | -17.7% | +14.1% | +29.4% |
Risk & Volatility
Evenly matched — CCRN and HCSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCSG currently trades 91.5% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.93x | 0.78x | 1.12x | 2.40x |
| 52-Week HighHighest price in past year | $93.50 | $14.99 | $24.39 | $70.43 |
| 52-Week LowLowest price in past year | $58.55 | $7.43 | $12.66 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +63.1% | +87.3% | +91.5% | +36.4% |
| RSI (14)Momentum oscillator 0–100 | 46.1 | 53.1 | 61.8 | 54.5 |
| Avg Volume (50D)Average daily shares traded | 171K | 552K | 676K | 34.9M |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: USPH as "Buy", CCRN as "Hold", HCSG as "Hold", HIMS as "Hold". Consensus price targets imply 72.9% upside for USPH (target: $102) vs -18.9% for CCRN (target: $11). USPH is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | $102.00 | $10.61 | $24.50 | $29.67 |
| # AnalystsCovering analysts | 12 | 14 | 15 | 19 |
| Dividend YieldAnnual dividend ÷ price | +3.1% | — | — | — |
| Dividend StreakConsecutive years of raises | 5 | 1 | 20 | — |
| Dividend / ShareAnnual DPS | $1.80 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +1.6% | +3.9% | +1.4% |
HIMS leads in 2 of 6 categories (Income & Cash Flow, Total Returns). HCSG leads in 2 (Profitability & Efficiency, Analyst Outlook). 2 tied.
USPH vs CCRN vs HCSG vs HIMS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is USPH or CCRN or HCSG or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Healthcare Services Group, Inc. (HCSG) offers the better valuation at 27. 5x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate U. S. Physical Therapy, Inc. (USPH) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — USPH or CCRN or HCSG or HIMS?
On trailing P/E, Healthcare Services Group, Inc.
(HCSG) is the cheapest at 27. 5x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, U. S. Physical Therapy, Inc. is actually cheaper at 20. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — USPH or CCRN or HCSG or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -43. 4% for U. S. Physical Therapy, Inc. (USPH). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — USPH or CCRN or HCSG or HIMS?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 209% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — USPH or CCRN or HCSG or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — USPH or CCRN or HCSG or HIMS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USPH leads at 10. 3% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is USPH or CCRN or HCSG or HIMS more undervalued right now?
On forward earnings alone, U.
S. Physical Therapy, Inc. (USPH) trades at 20. 6x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 113. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — USPH or CCRN or HCSG or HIMS?
In this comparison, USPH (3.
1% yield) pays a dividend. CCRN, HCSG, HIMS do not pay a meaningful dividend and should not be held primarily for income.
09Is USPH or CCRN or HCSG or HIMS better for a retirement portfolio?
For long-horizon retirement investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 3. 1% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (USPH: +22. 6%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between USPH and CCRN and HCSG and HIMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: USPH is a small-cap high-growth stock; CCRN is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. USPH pays a dividend while CCRN, HCSG, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.